CN103655563A - 抑制突变型c-kit的方法 - Google Patents

抑制突变型c-kit的方法 Download PDF

Info

Publication number
CN103655563A
CN103655563A CN201210378267.5A CN201210378267A CN103655563A CN 103655563 A CN103655563 A CN 103655563A CN 201210378267 A CN201210378267 A CN 201210378267A CN 103655563 A CN103655563 A CN 103655563A
Authority
CN
China
Prior art keywords
lailani
kit
proliferative disease
patient
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201210378267.5A
Other languages
English (en)
Chinese (zh)
Inventor
V·K·柴恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Priority to CN201810781649.XA priority Critical patent/CN109010340A/zh
Publication of CN103655563A publication Critical patent/CN103655563A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201210378267.5A 2012-09-26 2012-09-29 抑制突变型c-kit的方法 Pending CN103655563A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810781649.XA CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705838P 2012-09-26 2012-09-26
US61/705,838 2012-09-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810781649.XA Division CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Publications (1)

Publication Number Publication Date
CN103655563A true CN103655563A (zh) 2014-03-26

Family

ID=50295125

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210378267.5A Pending CN103655563A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法
CN201810781649.XA Pending CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810781649.XA Pending CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Country Status (8)

Country Link
US (3) US9480683B2 (es)
JP (1) JP6042157B2 (es)
KR (2) KR20140040594A (es)
CN (2) CN103655563A (es)
AU (1) AU2013204841B2 (es)
CA (1) CA2812258C (es)
MX (1) MX368707B (es)
TW (1) TWI599356B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107382983A (zh) * 2017-08-24 2017-11-24 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
WO2018014519A1 (zh) * 2016-07-18 2018-01-25 北京雅康博生物科技有限公司 用于检测c-kit基因突变的引物、探针及试剂盒

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
JP6042157B2 (ja) 2012-09-26 2016-12-14 アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，ＬＬＣ 変異型ｃ−ｋｉｔの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
CA3024012A1 (en) 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
DE102019204219A1 (de) * 2019-03-27 2020-10-01 Robert Bosch Gmbh Verfahren zur Diagnose von Abgassensoren
WO2021238957A1 (zh) * 2020-05-26 2021-12-02 江苏恒瑞医药股份有限公司 法米替尼在制备用于治疗c-KIT或PDGFRA突变的肿瘤的药物中的用途
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
WO2022173861A1 (en) * 2021-02-09 2022-08-18 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2004249511B2 (en) 2003-06-24 2011-01-20 Pfizer Products Inc. Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US20130230511A1 (en) * 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
JP6042157B2 (ja) 2012-09-26 2016-12-14 アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，ＬＬＣ 変異型ｃ−ｋｉｔの阻害方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL C. HEINRICH等人: "Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors", 《CLINICAL CANCER RESEARCH》 *
NANCY L. LEWIS等人: "Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014519A1 (zh) * 2016-07-18 2018-01-25 北京雅康博生物科技有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CN107382983A (zh) * 2017-08-24 2017-11-24 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法

Also Published As

Publication number Publication date
CA2812258C (en) 2016-12-13
US20160367545A1 (en) 2016-12-22
CN109010340A (zh) 2018-12-18
MX368707B (es) 2019-10-11
KR20170119659A (ko) 2017-10-27
US9889127B2 (en) 2018-02-13
MX2013010840A (es) 2015-04-27
AU2013204841B2 (en) 2016-04-28
KR101886006B1 (ko) 2018-08-06
US9480683B2 (en) 2016-11-01
US20140088147A1 (en) 2014-03-27
CA2812258A1 (en) 2014-03-26
TWI599356B (zh) 2017-09-21
US20180125839A1 (en) 2018-05-10
KR20140040594A (ko) 2014-04-03
JP6042157B2 (ja) 2016-12-14
JP2014065696A (ja) 2014-04-17
US10251877B2 (en) 2019-04-09
AU2013204841A1 (en) 2014-04-10
TW201417815A (zh) 2014-05-16

Similar Documents

Publication Publication Date Title
CN103655563A (zh) 抑制突变型c-kit的方法
US11608346B2 (en) Ras inhibitors
JP2023541236A (ja) Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用
AU2020379734A1 (en) Ras inhibitors
EP1797096B1 (en) Pyrazolopyrimidines as inhibitors of protein kinase b (akt)
EP2396330B1 (en) Fused pyrimidines
EP2396331B1 (en) Fused pyrimidines as akt inhibitors
JP2023509701A (ja) Ｓｈｐ２阻害剤投薬およびがんを処置する方法
JP2021506838A (ja) 非環式ｃｘｃｒ４阻害剤およびその使用
AU2022249177A1 (en) Methods for inhibiting ras
US20200016118A1 (en) Hdac inhibitor in combination with vegf/vegfr interaction for cancer therapy based on platelet count
Wu Exploiting replication stress induced by IGF blockade in cancer therapy
Johannessen Drugging Transcription: Exploring Roles of CDK8 From Cancer to Immunity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Texas in the United States

Applicant after: AROG PHARMACEUTICALS LLC

Address before: American Texas

Applicant before: AROG PHARMACEUTICALS LLC

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326